4SC in advanced licensing talks for its rheumatoid arthritis product

Friday 28 March 2008

The German drug developer, 4SC AG, said it has advanced negotiations with a number of pharmaceutical companies about licensing out its lead product for the treatment of rheumatoid arthritis, SC12267.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany